Health
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 | NEJM – nejm.org
Correspondence from The New England Journal of Medicine — SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
We conducted a global, randomized, placebo-controlled, phase 123 pivotal trial in which two 30-g doses of BNT162b2 (PfizerBioNTech) were administered 21 days apart (ClinicalTrials.gov number, NCT04368728). These doses of vaccine had mainly low-grade side…
Continue Reading
-
Noosa News19 hours agoLuxury caravan manufacturer Zone RV collapses into administration
-
General21 hours agoWoman in her 20s dies after dog attack in Western Australia’s north
-
General7 hours agoBoard stacking allegations as RACP directors call snap meeting
-
General19 hours agoCase against teens charged over Adelaide shopping centre stabbing could move to adult court